Fujifilm Diosynth Biotechnologies will provide commercial product supply of Jetrea (ocriplasmin) following ThromboGenics’ FDA approval for the treatment of Symptomatic Vitreomacular Adhesion (VMA).   The two companies entered a long-term commercial supply agreement for the manufacture of bulk substance in September 2010, following the completion of Phase III trials, and have partnered to complete validation and establish a well-characterized process.   Steve Bagshaw, managing director of Fujifil...